Prostate Cancer

Treatment Regret Infrequent After Radical Prostatectomy, IMRT

Treatment Regret Infrequent After Radical Prostatectomy, IMRT

Overall decision regret for 16.9% of patients; more regret for RP than radiotherapy component.

Radium-223 With Concomitant Therapy May Prolong Life With mCRPC

Radium-223 With Concomitant Therapy May Prolong Life With mCRPC

Survival was longer in patients who received radium-223 plus abiraterone, enzalutamide, or both.

High-Grade Prostate Cancer Linked to Diabetes Drugs

High-Grade Prostate Cancer Linked to Diabetes Drugs

By

Men who used the medications prior to radical prostatectomy had 83% greater odds of Gleason 7-10 tumors compared with non-users.

Radical Local Therapy Offers Mortality Benefit in Very High-Risk PCa

Radical Local Therapy Offers Mortality Benefit in Very High-Risk PCa

By

Prostatectomy and radiotherapy with or without ADT reduced prostate cancer-specific and all-cause mortality rates.

Adjuvant ADT May Up Mortality in Black Prostate Cancer Patients

Adjuvant ADT May Up Mortality in Black Prostate Cancer Patients

By

Androgen deprivation increased all-cause mortality risk by 77% among black men who underwent brachytherapy for favorable-risk prostate cancer.

Selenium May Cut Aggressive Prostate Cancer Risk

Selenium May Cut Aggressive Prostate Cancer Risk

An analysis of individual participant data from 15 prospective studies suggests a protective effect.

ED Drugs May Not Reduce Prostate Cancer Risk

ED Drugs May Not Reduce Prostate Cancer Risk

By

Prostate cancer was diagnosed in 19.5% of PDE5i users vs 22.7% of nonusers, a statistically insignificant difference.

Skeletal-Related Events Predict Higher Mortality in mCRPC

Skeletal-Related Events Predict Higher Mortality in mCRPC

By

Skeletal-related events occurred in 38% of patients with metastatic castration-resistant prostate cancer.

Intestinal Autoimmunity Possibly Linked to ADT

Intestinal Autoimmunity Possibly Linked to ADT

By

ADT for prostate cancer may be associated with a reduced risk of inflammatory bowel disease.

Identity Factors Influence Prostate Cancer Treatment Method

Identity Factors Influence Prostate Cancer Treatment Method

Ethnicity, education identified as factors that influence patients treatment decisions.

Obesity Common in Cancer Survivors

Obesity Common in Cancer Survivors

Prevalence of obesity is high in adults with a history of breast, prostate, or colorectal cancer.

Survival Outcomes in Gleason 9-10 PCa Similar With Radiation, Surgery

Survival Outcomes in Gleason 9-10 PCa Similar With Radiation, Surgery

By

External beam radiation therapy (EBRT) plus brachytherapy found to offer improved systemic control versus EBRT alone and radical prostatectomy.

Robotic, Open Prostate Cancer Surgery Offer Similar Early Results

Robotic, Open Prostate Cancer Surgery Offer Similar Early Results

By

No significant differences observed in standard oncologic outcomes and quality of life at 12 weeks.

Race Affects Switch From Prostate Cancer Observation to Active Therapy

Race Affects Switch From Prostate Cancer Observation to Active Therapy

By

Blacks found to be slightly more likely than whites to leave observational management to undergo radiotherapy or surgery.

PCa Active Surveillance Patients Enjoy Good Quality of Life

PCa Active Surveillance Patients Enjoy Good Quality of Life

By

Study finds no greater burden from untreated cancer among active surveillance patients.

Prostate Cancer Mortality Rate Highest Among Older Men

Prostate Cancer Mortality Rate Highest Among Older Men

By

Three quarters of PCa deaths occur among men diagnosed with the disease when they are 70 to 89 years old.

No Survival Benefit With Cabozantinib in Progressive mCRPC

No Survival Benefit With Cabozantinib in Progressive mCRPC

Cabozantinib did not increase survival of heavily treated patients with mCRPC, compared with prednisone.

Metastatic Prostate Cancer Cases Increasing

Metastatic Prostate Cancer Cases Increasing

Research emphasizes the need for nationwide refinements in the prostate cancer screening process.

PD-1 Blockade Shows Promise for mCRPC

PD-1 Blockade Shows Promise for mCRPC

By

In a small study, some men whose cancer progressed while on enzalutamide had a profound PSA response to pembrolizumab.

Prostate Multiparametric MRI Feasible for PCa Screening

Prostate Multiparametric MRI Feasible for PCa Screening

Adjusted odds ratio of prostate cancer significantly higher for MRI score than PSA.

Robot-Assisted Prostate Surgery Safe, Effective Long Term

Robot-Assisted Prostate Surgery Safe, Effective Long Term

By

Largest Asian series to date shows a 5-year biochemical recurrence-free survival rate of 76.4%.

Familial Risk of Aggressive Prostate Cancer Quantified

Familial Risk of Aggressive Prostate Cancer Quantified

By

Swedish researchers say their findings are more useful for counseling men with a family history of prostate cancer.

Prostate Cancer Patients Taking Statins Lived Longer

Prostate Cancer Patients Taking Statins Lived Longer

Study results strengthen researchers' arguments for further clinical trials evaluating the potential protective effect of statins.

PI3K Pathway Aberrations May Reveal Targeted Therapy Opportunities

PI3K Pathway Aberrations May Reveal Targeted Therapy Opportunities

Combination therapies targeting both mutations in the PI3K pathway and HER2 or hormone receptor overexpression should be evaluated, researchers say.

Benign Tissue Changes May Help Predict Post-RP Biochemical Recurrence

Benign Tissue Changes May Help Predict Post-RP Biochemical Recurrence

By

Preliminary findings suggest a field effect in prostate cancer.

Australian Docs Less Favorable to Post-RP Adjuvant Radiation Therapy

Australian Docs Less Favorable to Post-RP Adjuvant Radiation Therapy

Urologists in Australia less favorable toward adjuvant radiotherapy in 2015 vs 2012.

Expectant Management for PCa More Likely at Academic Centers

Expectant Management for PCa More Likely at Academic Centers

By

Odds of using this strategy are 2.7-fold greater vs community facilities.

Inherited Mutations Common Among Men With Metastatic Prostate Cancer

Inherited Mutations Common Among Men With Metastatic Prostate Cancer

By

Genetic testing results could help guide therapy for advanced prostate cancer.

Hypofractionated RT Noninferior for Localized Prostate Cancer

Hypofractionated RT Noninferior for Localized Prostate Cancer

For localized prostate cancer patients, hypofractionated radiation therapy at a dose of 60 Gy in fractions is effective.

Lymphovascular Invasion Helps Predict Post-RP Biochemical Recurrence

Lymphovascular Invasion Helps Predict Post-RP Biochemical Recurrence

By

About 10% of patients with clinically localized prostate cancer have lymphovascular invasion on their prostatectomy specimen.

Sign Up for Free e-newsletters